Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis-Reference-Cited by-同舟云学术

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

Published:2021-05 Issue: Volume:148 Page:411-421
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kim Youn H.,Prince H. Miles^ORCID,Whittaker Sean,Horwitz Steven M.,Duvic Madeleine,Bechter Oliver^ORCID,Sanches Jose A.^ORCID,Stadler Rudolf,Scarisbrick Julia^ORCID,Quaglino Pietro,Zinzani Pier Luigi^ORCID,Wolter Pascal,Eradat Herbert,Pinter-Brown Lauren C.,Ortiz-Romero Pablo L.,Akilov Oleg E.^ORCID,Trotman Judith,Taylor Kerry,Weichenthal Michael,Walewski Jan,Fisher David,McNeeley Marise,Gru Alejandro A.^ORCID,Brown Lisa,Palanca-Wessels M. Corinna^ORCID,Lisano Julie,Onsum Matthew,Bunn Veronica,Little Meredith,Trepicchio William L.,Dummer Reinhard

Funder

Seagen Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat;Rangwala;Blood Lymphat Canc,2012

2. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018;Gilson;Br J Dermatol,2019

3. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options;Li;Canc Manag Res,2012

4. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas;Willemze;Blood,2019

5. CD30 expression and proliferative fraction in nontransformed mycosis fungoides;Edinger;Am J Surg Pathol,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma;Blood Advances;2024-05-20

3. Advances in the pharmacological management of cutaneous T-cell lymphoma;Expert Opinion on Pharmacotherapy;2024-05-02

4. Mycosis fungoides: successful re-treatment with brentuximab vedotin;British Journal of Dermatology;2024-03-12

5. Rechallenge of brentuximab vedotin was effective for refractory mycosis fungoides: a case report;Journal of Cutaneous Immunology and Allergy;2024-01-25